JACC Report Card Highlights Inequities in CV Care, Death Rates

As we commemorate Juneteenth 2024, JACC, the flagship journal of the American College of Cardiology, has published “Excess Cardiovascular Mortality Among Black Americans 2000-2022: A Report Card,” to highlight the persistent and tragic inequities in cardiovascular care and put in human terms the years of life lost to the Black community because of their higher cardiovascular disease death rates.

JACC Incoming Editor-in-Chief Harlan M. Krumholz, MD, SM, FACC, said, the goal of the report card is to promote accountability and catalyze action that finally addresses this national tragedy.

“Our study reveals that Black Americans, because of their higher cardiovascular mortality rates compared with White Americans, have suffered almost 800,000 excess deaths, which translates to about 24 million additional years of life lost between 2000 and 2022,” Krumholz, who is also senior author of the study and the Harold H. Hines, Jr. Professor of Medicine at Yale School of Medicine said. “This staggering figure highlights the critical need for systemic changes in addressing cardiovascular inequities.”

In an accompanying editorial, Jennifer H. Mieres, MD, FACC, chair of the ACC Diversity and Inclusion Committee and Senior Vice President, Center for Equity of Care, at Northwell Health in New Hyde Park, New York, said the report card serves as a reminder that all Americans have not benefited equally from significant advances made in the treatment and prevention of cardiovascular diseases.

“We are reminded of the stark reality that Black Americans continue to face significant disparities in cardiovascular outcomes,” Mieres said. “Bringing an equity lens to the redesign of CV health by addressing the social determinants of health and the systemic barriers that contribute to structural racism are critical for solving for cardiovascular health disparities and ensuring equity of care.”

Social determinants of health have a detrimental impact in creating barriers that prevent the most vulnerable Americans from receiving the cardiovascular care they need. The ACC has established multiple programs to address these inequities. The Internal Medicine Program introduces groups who have been historically underrepresented in cardiology to a career in cardiology by connecting them with the mentors, peer network and resources they need to understand career opportunities in the field and be better prepared to address the unique and diverse health care challenges their patients face.

The Clinical Trials Research (CTR) program is intended to increase the number of individuals historically underrepresented in cardiology who serve as leaders in cardiovascular clinical trials research to ensure diversity of thought, experience and perspective, and ensure that the evidence base includes data more closely reflecting the demographics of actual cardiovascular patients.

SourceACC

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.